CX-1003 is under clinical development by Beijing Konruns Pharmaceutical and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CX-1003’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CX-1003 is under development for the treatment of solid tumors.The drug candidate is administered through oral route in the form of a tablet. It acts by targeting hepatocyte growth factor receptor and vascular endothelial growth factor receptor 2.
It was also under development for recurrent or metastatic solid tumors such as medullary thyroid carcinoma, renal cell carcinoma, lung cancer, liver cancer, gastric cancer, prostate cancer and radioactive iodine resistant thyroid cancer.
Beijing Konruns Pharmaceutical overview
Beijing Konruns Pharmaceutical (Konruns Pharmaceutical) is a pharmaceutical company. It develops hi-tech drugs for traditional and commercial purposes. The company offers products such as SuLing. Its SuLing is used to treat blood loss during hemorrhage and tumors. Konruns Pharmaceutical also offers services that include research, and development, new drug development, target selection, proval of conception, pre-clinical research, clinical research, registration and marketing, after marketing research, and compound screening. It is also involved in development of new drugs such as CX1026, CX1003, and KC1036. The company caters its products across China. Konruns Pharmaceutical is headquartered in Beijing, China.
For a complete picture of CX-1003’s drug-specific PTSR and LoA scores, buy the report here.